3.2. Analysis.
Comparison 3 Subcutaneous omalizumab + ICS and OCS versus placebo + ICS and OCS steroid (steroid reduction), Outcome 2 Number of participants with exacerbation.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.